Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 236 participants.

Also called NCT04532333

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 236 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04532333
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04532333. Randomized; no masking; primary purpose prevention. Start 2020-08 (anticipated); primary completion 2021-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms
Acronym
BUILD
Condition
Subarachnoid Hemorrhage, Aneurysmal
Intervention (Drug)
Bivalirudin 250 MG Injection
Intervention (Drug)
Heparin
Lead sponsor
Changhai Hospital (class: other)
Collaborator
The First Affiliated Hospital of Zhengzhou University (class: other)
Collaborator
Zhejiang University (class: other)
Collaborator
Wuhan University (class: other)
Collaborator
Qilu Hospital of Shandong University (class: other)
Collaborator
The First People's Hospital of Changzhou (class: other)

Record details

Record id
cardio:ct-nct04532333
Content hash
52aacb6b16b595deb8316ce42650b49f0743e8bf194ded2622d1b696de969c32